title: NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis.
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Landells
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Bhash
authors.initials: B
authors.lastname: Naidoo
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Clark
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D011358:Product Surveillance, Postmarketing; D011728:Pyridones / Q000627:therapeutic use*; D013222:State Medicine; D006113:United Kingdom; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D011728:Pyridones; C093844:pirfenidone